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Abstract
Background: Lipoprotein Lipase (LPL) deficiency is a rare autosomal recessive disorder with a heterogeneous clinical
presentation. Several mutations in the LPL gene have been identified to cause decreased activity of the enzyme.
Findings: An 11-week-old, exclusively breastfed male presented with coffee-ground emesis, melena, xanthomas,
lipemia retinalis and chylomicronemia. Genomic DNA analysis identified lipoprotein lipase deficiency due to
compound heterozygosity including a novel p.Q240H mutation in exon 5 of the lipoprotein lipase (LPL) gene.
His severe hypertriglyceridemia, including xanthomas, resolved with dietary long-chain fat restriction.
Conclusions: We describe a novel mutation of the LPL gene causing severe hypertriglyceridemia and report
the response to treatment. A review of the current literature regarding LPL deficiency syndrome reveals a few
potential new therapies under investigation.
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Findings
Exogenous lipid metabolism involves packaging of diet-
ary fat into chylomicrons in the small intestine, which
are later transported to the bloodstream. The initial step
of endogenous lipid metabolism involves the hydrolysis
of chylomicrons by lipoprotein lipase (LPL) [1]. LPL de-
ficiency is a rare autosomal recessive disorder with a
prevalence of 1 in 1,000,000 in the United States and
higher in other world regions, like Quebec, Canada due
to a founder effect [2]. The clinical presentation can in-
clude moderate or severe hypertriglyceridemia in af-
fected homozygotes or compound heterozygotes, while
simple heterozygote carriers often have normal lipids
[3]. Clinical features include eruptive xanthomas, ab-
dominal pain, hepato-splenomegaly, lower gastrointes-
tinal bleeding, recurrent pancreatitis, or lipemia retinalis
[4]. Dietary fat restriction is the cornerstone of treat-
ment, and gene therapy trials are ongoing [5].
Case report
We report the case of an 11-week-old male of Puerto
Rican descent who presented to the emergency depart-
ment with coffee-ground emesis, melena and a papular
rash. He was born full term to healthy, nonconsangui-
neous parents with a birth weight of 8 lb 4 oz and was
exclusively breast-fed. He had 4–5 episodes of coffee-
ground emesis, one episode of melena and a papular
rash (Fig. 1) that spread from his extremities to his trunk
over the course of 3 weeks. CBC revealed a hematocrit
of 17 % and his blood was grossly lipemic. A random
lipid panel showed triglycerides (TG) of 43,980 mg/dl.
The physical exam was notable for a well-appearing in-
fant with diffuse 2 mm yellow papules consistent with erup-
tive xanthomas and lipemia retinalis on fundoscopic exam.
Fasting lipid profile revealed total cholesterol 768 mg/dl,
TG 37,695 mg/dl, and HDL < 10 mg/dl. Breast-feeding was
discontinued and he was placed on Enfaport Lipil, a for-
mula with 84 % of fat content from medium-chain triglyc-
erides (MCT) and 16 % from long-chain fats. A repeat lipid
profile one month after the formula change revealed dra-
matic improvement in TG (Table 1). Two months after
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treatment, xanthomas and lipemia retinalis resolved; weight
gain and linear growth were normal. We hypothesized that
this child had an autosomal recessive mutation in the LPL
gene.
Methods
Ethics, consent and permission:Approval was obtained
from the Western University Ethics Review Board protocol
07920E and informed consent was obtained from both par-
ents. The parents gave their consent to publish this case.
Genomic DNA was isolated from whole blood using
Puregene DNA isolation kit (Gentra Systems, QIAGEN
Inc, Mississauga, ON, Canada). PCR amplifications were
performed using primers covering the coding regions and
~100 bp of intron-exon boundaries of the LPL gene as de-
scribed previously [3]. Bi-directional Sanger sequencing
was performed using established conditions [3] on an ABI
3730 DNA Analyzer (Applied Biosystems, Foster City,
CA, USA). DNA sequences were analyzed using SeqScape
v2.6 (Applied Biosystems, Foster City, CA, USA).
Results and discussion
We found that the proband was a compound heterozy-
gote for one novel and one reported mutation within
exon 5 of the LPL gene (Fig. 2). The first mutation
p.G215E was a heterozygous transition c.644G→A,
resulting in a substitution of glycine to glutamic acid at
amino acid 215 (identical to residue 188 in the mature
protein). This mutation has been previously reported to
cause LPL deficiency [6]. The second, novel mutation
p.Q240H was a heterozygous transversion c.721G→T,
causing an amino acid substitution of glutamine to histi-
dine at residue 240 (identical to residue 213 in the ma-
ture protein). In silico software programs PolyPhen2 and
SIFT both predicted that this mutation was probably
damaging. Both parents' DNA samples were sequenced:
the LPL p.Q240H mutation was found in the father and
the p.G215E mutation was found in the mother.
LPL plays a role in multiple stages of lipid metabolism,
including hydrolysis of chylomicrons. LPL is primarily
synthesized by myocytes and adipocytes and recent stud-
ies have identified glycosylphosphatidylinositol-anchored
high-density lipoprotein-binding protein 1 (GPIHBP1) as
the molecule responsible for transporting LPL to the ca-
pillary lumen [7]. LPL deficiency is a rare autosomal re-
cessive disorder caused by decreased LPL activity due to
mutations in the LPL gene [2]. The LPL gene is located
on chromosome 8p21.3 and contains 10 exons, span-
ning ~ 30 kb and encodes a mature protein of 448 amino
acids [8]. Most mutations are found in exons 4, 5 and 6
and although missense mutations are more common,
nonsense, frameshift, insertion, deletion and duplication
mutations have also been described [9]. The mutation
in this patient expands the spectrum of known patho-
genic LPL mutations to more than 150. It also occurs
in a region of the protein that has to date been rela-
tively bereft of reported mutations. The involvement
of amino acid residue 240 also highlights the func-
tional importance of the local domain in lipolysis of
triglyceride-rich lipoproteins.
To date, genotype-phenotype correlations have not
been identified [2, 10]. Patients who are homozygous or
compound heterozygotes can present with marked
hypertriglyceridemia. Heterozygote patients can have
normal or mildly elevated TG levels [3]. Both parents of
our patient are heterozygous carriers of LPL gene muta-
tions and had normal lipids.
The clinical manifestations of LPL deficiency are
heterogeneous. Eruptive xanthomas appear mostly on
shoulders, buttocks and extensor surfaces of the
limbs when the TG levels exceed 2000 mg/dl [11].
Lipemia retinalis involving the peripheral vessels can
be seen with TG levels over 2,500 mg/dl and as the
levels increase, the damage extends to the posterior
Fig. 1 Eruptive xanthomas on the right sole
Table 1 Plasma lipid levels of the proband at baseline and after 1 month of dietary fat restriction, and both parents
Lipid profile Proband Mother Father
Baseline (non-fasting) Baseline (fasting) After dietary change
TG (mg/dl) 43,980 37,695 375 87 78
TC (mg/dl) 761 768 98 190 127
HDL (mg/dl) 37 <10 21 43 41
LDL (mg/dl) Unable to measure Unable to measure 2 130 70
TG triglycerides, TC total cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein
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pole [12]. Abdominal pain and gastrointestinal
hemorrhage have been attributed to hyperviscosity sec-
ondary to elevated TG [13]. Pancreatitis is common in
these patients and risk increases with TG levels over
1,000 mg/dl [14]. Therefore, the goal of therapy is to
decrease TG levels < 1,000 mg/dl [15].
Dietary restriction remains the cornerstone of treat-
ment and fat supplements using MCT are useful since
they are absorbed directly into the portal vein [15].
Long-term data on patients with LPL deficiency are
limited but show normal linear growth and puberty
despite dietary fat restriction [4]. Even with recurrent
pancreatitis, this population does not demonstrate a
high mortality rate [16]. Satisfactory TG levels can be
difficult to achieve with diet restriction alone. Drug
therapy using gemfibrozil, omega-3 fatty acids and
orlistat may decrease TG levels when combined with
a fat-restricted diet however, the use of these drugs is
controversial [3, 17, 18]. Therapy involving intramus-
cular introduction of a gain-of-function variant of the
LPL gene is approved in Europe, although is costly
and has only a transient effect [5]. A promising treat-
ment approach currently under investigation is orally-
administered diacylglycerol O-acyltransferase 1 (DGAT1)
inhibitors targeting DGAT1, which mediates triglyceride
synthesis during dietary fat absorption [19].
Our patient is a compound heterozygote who has a
novel p.Q240H mutation in exon 5 of the LPL gene
causing severe hypertriglyceridemia. Although his TG
levels are much improved with MCT-based formula, the
challenge will be maintaining those levels with dietary
fat restriction as table foods are introduced and he grows
through childhood.
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Fig. 2 Segregation of LPL mutations in index family. Pedigree structure and DNA sequence electropherogram tracings of the LPL gene in the
vicinity of codons 215 and 240 for each family member are shown. Three letter nucleotide sequences, single letter amino acid codes, and codon
numbers corresponding to amino acid residues are indicated. Asterisks show heterozygosity at the specific amino acid position: the father is a
simple heterozygote for the p.Q240H mutation, the mother is a simple heterozygote for the p.G215E mutation and the proband is a compound
heterozygote for both mutations
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